CD276 and breast carcinoma: In addition to the PD-1/PD-L1 pathway, there are several other immune checkpoint receptors and ligands, such as B7-H3 and B7-H4, whose upregulation on tumor cells or tumor-infiltrating cells may influence breast cancer immune escape (104).